Physician profile
Ferdinand Q Alcaide
NPI 1356337679
$4,989.26
in general payments reported to CMS, 2019-2025
29 companies · $1,450 in 2025
The $1,450 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601 · 2020: $130 · 2021: $289 · 2022: $577 · 2023: $1,045 · 2024: $898 · 2025: $1,450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,171 · Education: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,171.40 |
| Education | $222.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $887.15 | 2019-2025 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $464.33 | 2019-2025 | Vafseo, Auryxia |
| Opko Pharmaceuticals, LLC | $450.35 | 2019-2025 | Rayaldee |
| Travere Therapeutics, INC. | $314.32 | 2020-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $303.18 | 2019-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $275.35 | 2022-2025 | |
| Amgen INC. | $271.61 | 2019-2025 | Krystexxa, Tavneos |
| Baxter Healthcare | $251.75 | 2019-2024 | Renal - Pd, Renal - Acute |
| Novo Nordisk INC | $221.89 | 2024-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $206.29 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $182.41 | 2021-2025 | Acthar |
| Glaxosmithkline, LLC. | $169.01 | 2023-2024 | Benlysta, Jesduvroq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.63 | 2024-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $96.38 | 2022-2025 | Tarpeyo |
| Alnylam Pharmaceuticals INC. | $92.31 | 2021-2024 | Oxlumo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valeritas, INC. | $90.00 | 2019 | |
| Ardelyx, INC. | $85.47 | 2024-2025 | Ibsrela |
| Amarin Pharma, INC. | $81.47 | 2019 | |
| Fresenius USA Marketing, INC. | $77.17 | 2022-2024 | |
| Horizon Therapeutics Plc | $74.43 | 2019-2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $60.08 | 2022-2023 | Soliris |
| Cormedix INC. | $58.48 | 2024 | Defencath |
| Vifor Pharma, INC. | $37.15 | 2019-2023 | Veltassa |
| Aurinia Pharma U.S., INC. | $35.36 | 2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $26.68 | 2025 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $23.12 | 2019 | |
| Shield Therapeutics INC | $17.46 | 2025 | |
| Fresenius USA Manufacturing, INC. | $15.49 | 2025 | |
| Cardiovascular Systems INC. | $12.94 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ferdinand Alcaide listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.